Something must be done—but chemotherapy isn’t the only option

Wise challenges the usefulness of chemotherapy drugs in patients with metastatic cancer,1 and Hewlett “gets it” that a survival benefit of only a few months may not be fundable from a health economist’s point of view.2 Understandably, though, Hewlett highlights the potential personal benefit of chemotherapy.

So …